Market Summary
USD66.97-0.27
Delayedas of 23 Mar 2023, 01:26 pm-0.40%
BMY Stock Price
BMY RSI Chart
BMY Valuation
BMY Price/Sales (Trailing)
BMY Profitability
BMY Fundamentals
BMY Revenue
BMY Earnings
Price Action
52 Week Range
65.2881.44
(Low)(High)
Last 7 days
0.3%
Last 30 days
-7.8%
Last 90 days
-10.0%
Trailing 12 Months
-1.1%
BMY Financial Health
BMY Investor Care
Peers (Alternatives to Bristol-Myers Squibb)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
JNJ | 396.9B | 94.9B | -5.16% | -10.64% | 22.12 | 4.18 | 1.25% | -14.07% |
LLY | 298.8B | 28.5B | -5.67% | 20.74% | 47.85 | 10.47 | 0.79% | 11.88% |
MRK | 272.8B | 59.3B | -1.75% | 40.02% | 17.88 | 4.63 | 21.72% | 11.27% |
PFE | 226.2B | 100.3B | -8.43% | -20.95% | 7.21 | 2.25 | 23.43% | 42.74% |
BMY | 142.4B | 46.2B | -7.78% | -1.12% | 22.5 | 3.08 | -0.49% | -9.54% |
| MID-CAP | ||||||||
PRGO | 4.5B | 4.5B | -0.20% | -5.41% | -32.05 | 1.01 | 7.56% | -104.06% |
RETA | 3.3B | 2.2M | 105.10% | 171.03% | -10.52 | 1.5K | -80.71% | -4.88% |
| SMALL-CAP | ||||||||
SUPN | 1.9B | 667.2M | -9.96% | 17.66% | 31.57 | 2.87 | 15.09% | 13.64% |
TLRY | 1.6B | 602.5M | -17.77% | -52.80% | -2.78 | 2.67 | 18.18% | -18.59% |
CGC | 923.6M | 478.9M | -11.35% | -65.42% | -0.29 | 1.93 | -31.50% | -634.70% |
INVA | 792.9M | 285.2M | -7.22% | -37.95% | 3.6 | 2.78 | -27.21% | -40.28% |
CRON | 726.9M | 114.5M | -15.28% | -37.42% | -4.31 | 6.35 | 27.90% | 57.40% |
ACRS | 539.5M | 29.8M | -40.95% | -47.43% | -6.21 | 18.13 | 340.05% | 4.35% |
OCUL | 400.7M | 51.5M | -2.49% | -0.39% | -5.64 | 7.78 | 18.32% | -984.05% |
ENDP | 94.1M | 2.3B | -43.99% | -88.43% | -0.03 | 0.04 | -22.53% | -376.66% |
Financials for Bristol-Myers Squibb
| Income Statement (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Revenue | -1.2% | 46,159 | 46,738 | 47,144 | 46,960 | 46,385 |
| S&GA Expenses | -1.1% | 7,814 | 7,902 | 7,760 | 7,855 | 7,690 |
| R&D Expenses | -0.1% | 9,509 | 9,517 | 10,079 | 10,236 | 10,195 |
| Costs and Expenses | -1.5% | 38,446 | 39,026 | 39,484 | 39,705 | 38,287 |
| EBITDA | -0.3% | 19,389 | 19,446 | 19,546 | 19,355 | - |
| EBITDA Margin | 1.0% | 0.42* | 0.42* | 0.42* | 0.41* | - |
| Earnings Before Taxes | 0.0% | 7,713 | 7,712 | 7,660 | 7,255 | 8,098 |
| EBT Margin | 1.3% | 0.17* | 0.17* | 0.16* | 0.15* | - |
| Interest Expenses | -0.9% | 1,400 | 1,413 | 1,442 | 1,500 | - |
| Net Income | -5.2% | 6,327 | 6,677 | 6,617 | 6,251 | 6,994 |
| Net Income Margin | -4.1% | 0.14* | 0.14* | 0.14* | 0.13* | - |
| Free Cahsflow | -6.1% | 11,948 | 12,725 | 14,281 | 15,142 | - |
| Balance Sheet | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Assets | -1.4% | 96,820 | 98,196 | 100,357 | 103,034 | 109,314 |
| Current Assets | 1.8% | 27,273 | 26,796 | 30,186 | 30,121 | 33,262 |
| Cash Equivalents | 18.0% | 9,123 | 7,734 | 10,750 | 12,369 | 13,979 |
| Inventory | 12.8% | 2,339 | 2,074 | 2,142 | 2,104 | 2,095 |
| Net PPE | 3.6% | 6,255 | 6,035 | 5,970 | 6,047 | 6,049 |
| Goodwill | 0.2% | 21,149 | 21,112 | 20,446 | 20,500 | 20,502 |
| Liabilities | 0.4% | 65,702 | 65,462 | 67,696 | 71,389 | 73,308 |
| Current Liabilities | 15.6% | 21,890 | 18,930 | 20,915 | 22,821 | 21,868 |
| LT Debt, Current | -59.0% | 1,903 | 4,646 | 7,297 | 4,764 | - |
| LT Debt, Non Current | -5.2% | 35,056 | 36,966 | 37,107 | 37,450 | 39,605 |
| Shareholder's Equity | -4.9% | 31,061 | 32,671 | 32,600 | 31,580 | 35,946 |
| Retained Earnings | 3.4% | 25,503 | 24,675 | 24,217 | 23,948 | 23,820 |
| Additional Paid-In Capital | 0.5% | 45,165 | 44,956 | 44,375 | 43,756 | 44,361 |
| Shares Outstanding | -0.4% | 2,126 | 2,135 | 2,129 | - | - |
| Minority Interest | -9.5% | 57.00 | 63.00 | 61.00 | 65.00 | 60.00 |
| Cashflow (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Cashflow From Operations | -5.4% | 13,066 | 13,817 | 15,396 | 16,195 | 16,207 |
| Share Based Compensation | -3.0% | 457 | 471 | 498 | 539 | 583 |
| Cashflow From Investing | 43.3% | -1,062 | -1,874 | -769 | -300 | -538 |
| Cashflow From Financing | 4.1% | -16,962 | -17,683 | -14,920 | -14,582 | -16,224 |
| Dividend Payments | 1.0% | 4,634 | 4,588 | 4,524 | 4,473 | 4,396 |
| Buy Backs | -5.3% | 8,001 | 8,452 | 8,276 | 9,512 | 6,287 |
Risks for BMY
What is the probability of a big loss on BMY?
48.1%
Probability that Bristol-Myers Squibb stock will be more than 20% underwater in next one year
1.9%
Probability that Bristol-Myers Squibb stock will be more than 30% underwater in next one year.
0%
Probability that Bristol-Myers Squibb stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does BMY drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Bristol-Myers Squibb was unfortunately bought at previous high price.
Drawdowns
Returns for BMY
Cumulative Returns on BMY
8.6%
10-Year Cumulative Returns
4.0%
7-Year Cumulative Returns
3.2%
5-Year Cumulative Returns
10.1%
3-Year Cumulative Returns
What are the long-term rolling returns for BMY?
FIve years rolling returns for Bristol-Myers Squibb.
Annualized Returns
Which funds bought or sold BMY recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-03-15 | B. Riley Wealth Advisors, Inc. | added | 5.8 | 1,002,450 | 15,186,500 | 0.42% |
2023-03-13 | Claro Advisors LLC | added | 20.27 | 145,154 | 1,313,150 | 0.43% |
2023-03-10 | MATHER GROUP, LLC. | added | 61.00 | 277,270 | 717,270 | 0.01% |
2023-03-10 | BAILLIE GIFFORD & CO | unchanged | - | -47.00 | 32,953 | -% |
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | reduced | -1.68 | -802,303 | 160,959,000 | 0.18% |
2023-03-08 | SHEETS SMITH WEALTH MANAGEMENT | added | 0.42 | 71,000 | 4,437,000 | 0.69% |
2023-03-08 | Capital Asset Advisory Services LLC | added | 16.1 | 293,781 | 1,843,780 | 0.15% |
2023-03-06 | Rockefeller Capital Management L.P. | reduced | -3.37 | -1,172,000 | 52,076,000 | 0.26% |
2023-03-06 | BIRMINGHAM CAPITAL MANAGEMENT CO INC/AL | unchanged | - | 38,515 | 3,195,520 | 1.21% |
2023-03-06 | NORTH STAR ASSET MANAGEMENT INC | reduced | -8.03 | -56,783 | 769,217 | 0.05% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Bristol-Myers Squibb News
Schedule 13G FIlings of Bristol-Myers Squibb
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 09, 2023 | vanguard group inc | 9.54% | 202,927,620 | SC 13G/A | |
| Feb 07, 2023 | blackrock inc. | 8.1% | 172,720,377 | SC 13G/A | |
| Feb 09, 2022 | vanguard group inc | 9.00% | 199,834,483 | SC 13G/A | |
| Feb 01, 2022 | blackrock inc. | 7.6% | 169,226,706 | SC 13G/A | |
| Feb 10, 2021 | vanguard group inc | 8.82% | 199,340,458 | SC 13G/A | |
| Jan 29, 2021 | blackrock inc. | 7.6% | 172,464,804 | SC 13G/A | |
| Feb 12, 2020 | vanguard group inc | 8.32% | 194,860,154 | SC 13G/A | |
| Feb 05, 2020 | blackrock inc. | 7.3% | 171,343,446 | SC 13G/A | |
| Jan 28, 2020 | wellington management group llp | 3.57% | 83,470,877 | SC 13G/A |
BMY Fair Value
Bristol-Myers Squibb fair value in different scenarios
The table shows the Fair Value estimates for Bristol-Myers Squibb for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
| Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
|---|---|---|---|---|---|
| Very Low Inflation | - - | - - | - - | - - | - - |
| Current Inflation | 33.86 -49.44% | 40.90 -38.93% | 62.78 -6.26% | 117.02 74.73% | 143.97 114.98% |
| Very High Inflation | - - | - - | - - | - - | - - |
Historical Bristol-Myers Squibb Fair Value Estimates
Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price
Recent SEC filings of Bristol-Myers Squibb
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Mar 14, 2023 | 4 | Insider Trading | |
| Mar 14, 2023 | 4 | Insider Trading | |
| Mar 14, 2023 | 4 | Insider Trading | |
| Mar 14, 2023 | 4 | Insider Trading | |
| Mar 14, 2023 | 4 | Insider Trading | |
| Mar 14, 2023 | 4 | Insider Trading | |
| Mar 14, 2023 | 4 | Insider Trading | |
| Mar 14, 2023 | 4 | Insider Trading | |
| Mar 14, 2023 | 4 | Insider Trading | |
| Mar 14, 2023 | 4 | Insider Trading |
Latest Insider Trading transactions for BMY
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-03-10 | Mily Elizabeth | acquired | - | - | 3,458 | evp, strategy & bd |
2023-03-10 | Powell Ann | sold (taxes) | -1,104,590 | 65.71 | -16,810 | evp, chief human resources |
2023-03-10 | Hirawat Samit | acquired | - | - | 38,978 | evp,chief med.offr.,drug dev. |
2023-03-10 | BOERNER CHRISTOPHER S. | acquired | - | - | 8,568 | evp, chief commercial officer |
2023-03-10 | LEUNG SANDRA | acquired | - | - | 8,731 | evp, general counsel |
2023-03-10 | Mily Elizabeth | sold (taxes) | -922,568 | 65.71 | -14,040 | evp, strategy & bd |
2023-03-10 | Hirawat Samit | sold (taxes) | -1,471,580 | 65.71 | -22,395 | evp,chief med.offr.,drug dev. |
2023-03-10 | Mily Elizabeth | acquired | - | - | 29,636 | evp, strategy & bd |
2023-03-10 | Elkins David V | acquired | - | - | 71,871 | evp, chief financial officer |
2023-03-10 | Caforio Giovanni | acquired | - | - | 234,676 | board chair and ceo |
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
BMY Income Statement
2022-12-31CONSOLIDATED STATEMENTS OF EARNINGS - USD ($) $ in Millions | 12 Months Ended | ||||
|---|---|---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |||
| Total Revenues | $ 46,159 | $ 46,385 | $ 42,518 | ||
| Cost of products sold | [1] | 10,137 | 9,940 | 11,773 | |
| Marketing, selling and administrative | 7,814 | 7,690 | 7,661 | ||
| Research and development | 9,509 | 10,195 | 10,048 | ||
| Acquired IPRD | 815 | 1,159 | 12,533 | ||
| Amortization of acquired intangible assets | 9,595 | 10,023 | 9,688 | ||
| Other (income)/expense, net | 576 | (720) | (2,314) | ||
| Total Expenses | 38,446 | 38,287 | 49,389 | ||
| Earnings/(Loss) Before Income Taxes | 7,713 | 8,098 | (6,871) | ||
| Provision for Income Taxes | 1,368 | 1,084 | 2,124 | ||
| Net Earnings/(Loss) | 6,345 | 7,014 | (8,995) | ||
| Noncontrolling Interest | 18 | 20 | 20 | ||
| Net Earnings(Loss) Attributable to BMS | $ 6,327 | $ 6,994 | $ (9,015) | ||
| Earnings per common share attributable to BMS, basic (in usd per share) | $ 2.97 | $ 3.15 | $ (3.99) | ||
| Earnings per common share attributable to BMS, diluted (in usd per share) | $ 2.95 | $ 3.12 | $ (3.99) | ||
| Net product sales | |||||
| Total Revenues | $ 44,671 | $ 45,055 | $ 41,321 | ||
| Alliance and other revenues | |||||
| Total Revenues | $ 1,488 | $ 1,330 | $ 1,197 | ||
| |||||
BMY Balance Sheet
2022-12-31CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions | Dec. 31, 2022 | Dec. 31, 2021 |
|---|---|---|
| Current Assets: | ||
| Cash and cash equivalents | $ 9,123 | $ 13,979 |
| Marketable debt securities | 130 | 2,987 |
| Receivables | 9,886 | 9,369 |
| Inventories | 2,339 | 2,095 |
| Other current assets | 5,795 | 4,832 |
| Total Current Assets | 27,273 | 33,262 |
| Property, plant and equipment | 6,255 | 6,049 |
| Goodwill | 21,149 | 20,502 |
| Other intangible assets | 35,859 | 42,527 |
| Deferred income taxes | 1,344 | 1,439 |
| Other non-current assets | 4,940 | 5,535 |
| Total Assets | 96,820 | 109,314 |
| Current Liabilities: | ||
| Short-term debt obligations | 4,264 | 4,948 |
| Accounts payable | 3,040 | 2,949 |
| Other current liabilities | 14,586 | 13,971 |
| Total Current Liabilities | 21,890 | 21,868 |
| Deferred income taxes | 2,166 | 4,501 |
| Long-term debt | 35,056 | 39,605 |
| Other non-current liabilities | 6,590 | 7,334 |
| Total Liabilities | 65,702 | 73,308 |
| Commitments and contingencies | ||
| Bristol-Myers Squibb Company Shareholders’ Equity: | ||
| Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 2,991 in 2022 and 3,484 in 2021, liquidation value of $50 per share | 0 | 0 |
| Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.9 billion issued in 2022 and 2021 | 292 | 292 |
| Capital in excess of par value of stock | 45,165 | 44,361 |
| Accumulated other comprehensive loss | (1,281) | (1,268) |
| Retained earnings | 25,503 | 23,820 |
| Less cost of treasury stock — 825 million common shares in 2022 and 747 million common shares in 2021 | (38,618) | (31,259) |
| Total Bristol-Myers Squibb Company Shareholders’ Equity | 31,061 | 35,946 |
| Noncontrolling interest | 57 | 60 |
| Total Equity | 31,118 | 36,006 |
| Total Liabilities and Equity | $ 96,820 | $ 109,314 |